@entity231 surgery outcomes in corneal refractive surgery eyes: Study from the European Registry of Quality Outcomes for XXXX and Refractive Surgery.

@entity1 @entity231
PURPOSE: To analyze visual outcomes after @entity231 surgery in @entity1 with previous corneal refractive surgery. SETTING: @entity231 surgery clinics in 18 European countries and Australia. DESIGN: Database study. METHODS: Cases of @entity231 extraction with corneal refractive surgery eyes (corneal refractive cases) were identified from all @entity231 extractions reported to the European Registry of Quality Outcomes for @entity231 and Refractive Surgery database over a 5-year period. Preoperative and postoperative measurements and trends over time were analyzed. RESULTS: Of 807,220 @entity231 extractions, 1229 (0.15%) were corneal refractive cases. There was a significant increase, over time, in the number of corneal refractive cases (P < .001). Corneal refractive @entity1 were younger than @entity1 without corneal refractive surgery (nonrefractive @entity1 ) (62.9 years versus 74.0 years; P < .001) but had similar mean preoperative and postoperative corrected-distance visual acuity (CDVA) (preoperative logMAR 0.44[6/16] for both [P = .286]; postoperative logMAR 0.06[6/7] for both [P = .245]). Postoperative CDVA was worse than preoperative CDVA in 35 (4%) corneal refractive and 8,999 (1.5%) nonrefractive @entity1 (P  <  .001). In all, 74 (8.5%) of 873 corneal refractive versus 16,566 (2.8%) /584,496 nonrefractive @entity1 , having @entity231 surgery, had preoperative CDVA of logMAR 0.0[6/6] or better (P < .001). Nineteen (54.3%) of 35 corneal refractive case @entity1 who had worse postoperative CDVA had preoperative CDVA of logMAR 0.0(6/6) or better. CONCLUSION: @entity231 surgery has been reported with increasing frequency in corneal refractive surgery @entity1 , since 2008. These @entity1 had preoperative CDVA similar to those of @entity1 without previous corneal refractive surgery but were younger and were at higher risk of worse postoperative CDVA, especially if they had preoperative CDVA of logMAR 0.0(6/6) or better. FINANCIAL DISCLOSURE: No author has any financial or proprietary interest in any material, or method, mentioned.
